닫기
검색

Pipeline

Filters
Pipeline
NN2101
Indications
Retinal Diseases including DR/DME and wAMD
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Fully human IgG1 monoclonal antibody discovered by Novelty Nobility
Target
cKIT (CD117 or Stem Cell Factor Receptor)
Science
Unlike most investigational retinal therapies which are currently participating in a race to increase the durability of anti-VEGF therapies, we focus on the fundamentals of the retinal diseases — hypoxia. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor stabilized by hypoxia, playing a pivotal role in the onset and development of retinal diseases. Interestingly, our cKIT inhibitor NN2101 regulates HIF-1α and mediates vascular permeability, inducing vessel normalization and resolution of hypoxia. We dream of curing retinal diseases.

Publications

1. [ARVO Poster] The novel function of NN2101, an anti-c-kit antibody, as an inhibitor of HIF via c-kit regulation in retinal neovascularization and neurodegeneration (2022)

2. [Pharmaceutics] A Fully Human Monoclonal Antibody Targeting cKIT Is a Potent Inhibitor of Pathological CNV in Mice (2021) 

3. [IJBIOMAC] Development and characterization of a fully human antibody targeting SCF/c-kit signaling (2020)

4. [ATVB] SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization (2019)

5. [Mol Vis.] Src tyrosine kinase regulates the stem cell factor-induced breakdown of the blood-retinal barrier (2016)

6. [ATVB] Stem Cell Factor Is a Potent Endothelial Permeability Factor (2014)

7. [Cardiovasc Res.] Direct and Differential Effects of Stem Cell Factor on the Neovascularization Activity of Endothelial Progenitor Cells (2011)


Pipeline
NN3201
Indications
cKIT positive Cancers including SCLC, AML/CML, and GIST
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Novel antibody-drug conjugate (ADC) designed and created by Novelty Nobility- Fully human IgG1 monoclonal antibody discovered by Novelty Nobility conjugated with ThioBridge®, a proprietary site-specific ADC cleavable linker technology of Abzena, and MMAE with DAR 4
Target
cKIT (CD117 or Stem Cell Factor Receptor)
Science
Developed to treat both cKIT wildtype and activating mutation-driven cancers, NN3201 monotherapy exhibited complete remission in all tested xenograft model studies of hard-to-treat cancers such as SCLC and AML. This novel ADC is powered by dual modalities that simultaneously address the tumor microenvironment (TME) via cKIT pathway inhibition and by targeting cKIT positive tumors for ADC internalization. NN3201 also demonstrates a superior preclinical safety profile with a large therapeutic index.
Publications

1. [AACR poster] An Optimized Preclinical Antibody-Drug Conjugate Against Cancers with cKIT Overexpression or Activating Mutations

2. [Int. J. Mol. Sci.] Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer (2022)

3. [Mol. Oncol.] A novel anti-c-Kit ADC to treat wild-type and activating-mutant c-Kit-positive tumors (2021)

Pipeline
NN3206
Indications
Pan RAS-driven Cancers
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Novel antibody-drug conjugate (ADC) created by Novelty Nobility
Target
Undisclosed
Science
An undruggable target from a traditional antibody perspective, RAS mutations regulate induction of a certain membrane protein, our undisclosed target. Pan RAS mutations and overexpression of our undisclosed target are found to be highly correlated in various RAS-driven tumors. As such, NN3206 is designed to demonstrate superb RAS subtype- or mutation-agnostic pharmacological activities.
Pipeline
NN2802
Partnership
Indications
Chronic urticaria, adjunct to allergen immunotherapy
  • Research
  • Preclinical
  • Phase I
  • Phase II/III
Learn More
Details
Fully human IgG1 monoclonal antibody discovered by Novelty Nobility
Target
cKIT (CD117 or Stem Cell Factor Receptor)
Science
cKIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. cKIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Our anti-cKIT antibody specifically binds cKIT with high specificity and potently inhibits its activity.